IP Library Granted Patent US 12,611,439
Granted Patent B2
US 12,611,439 · App. 18/166,973 · Granted Apr 28, 2026

Ionic self-assembling peptides

Inventors: Eun Seok Gil (Acton, MA); Elton Aleksi (West Roxbury, MA); Naoki Yamamoto (Yamanashi Prefecture, JP)
Assignee: 3-D Matrix, Ltd.
A61K38/10A61K9/06A61K9/08A61K38/39A61K47/02A61P19/04A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,611,439
App. No.
18/166,973
Granted
Apr 28, 2026
Kind
B2
Abstract

Provided herein are ionic self-assembling peptides, pharmaceutical compositions comprising the peptides, and methods of using and making the same.

Claims (20)

1 . A method of making a self-assembling peptide, wherein the self-assembling peptide comprises the amino acid sequence set forth in SEQ ID NO: 15, wherein the method comprises synthesizing the self-assembling peptide by an automated peptide synthesizer and providing the self-assembling peptide in a powder or a solution form.

2 . The method of claim 1 , comprising including in the peptide one or both of,

a) an N-terminal functional group selected from the group consisting of an acetyl, a formyl, pyroglutamyl (pGlu), biotin, polyethylene glycol (PEG), urea, alkylamine, a carbamate, a sulfonamide, dansyl, 2,4-dintrophenyl, fluorescein, 7-methoxycoumarin acetic acid, 9-fluorenylmethyloxycarbonyl, succinyl, chloroacetyl, maleimide, benzyloxycarbonyl, bromoacetyl, nitrilotriacetyl, tertbutoxycarbonyl, 4-hydroxyphenylpropionic acid, allyloxycarbonyl, a fatty acid, and trityl, and

b) a C-terminal functional group selected from the group consisting of an amine, an amido, an N-alkyl amide, an aldehyde, an ester, an alcohol, para-nitroanilide (pNA), 7-amino-4-methylcoumarin (Amc), a hydrazide, hydroxamic acid, chloromethylketone, p-nitroaniline, para-nitrophenol, fluoromethylketone, and cysteamide.

3 . A method of making a pharmaceutical composition, comprising adding a self-assembling peptide in the powder form to water according to claim 1 or providing the self-assembling peptide according to claim 1 in aqueous solution.

4 . The method of claim 3 , comprising adding a tonicity agent wherein the tonicity agent comprises: one or more salts selected from the group consisting of NaCl, KCl, MgCl 2 , CaCl 2 ), NH 4 Cl, Na 2 HPO 4 , KH 2 PO 4 , and CaSO 4 ; and/or

one or more sugars selected from the group consisting of dextrose, mannitol, glycerin, sucrose, and trehalose.

5 . The method of claim 4 , wherein the tonicity agent comprises one or more salts and is present in a concentration of about 0.01 M to about 0.3 M.

6 . The method of claim 4 , wherein the tonicity agent comprises one or more sugars and is present in a concentration of about 0.1-10% (w/v).

7 . The method of claim 3 , wherein the pharmaceutical composition has a pH of from about 6 to about 8.

8 . The method of claim 7 , wherein the net charge of the self-assembling peptide in the pharmaceutical composition is greater than or equal to +1 or less than or equal to −1.

9 . The method of claim 3 , wherein the concentration of the self-assembling peptide in the pharmaceutical composition is from about 0.01% (w/v) to about 10% (w/V).

10 . The method of claim 3 , wherein the pharmaceutical composition further comprises an isolated cell.

11 . The method of claim 10 , wherein the isolated cell is a mammalian cell selected from the group consisting of: an immune cell, a stem cell, chondrocyte progenitor cells, pancreatic progenitor cells, myoblasts, fibroblasts, keratinocytes, neuronal cells, glial cells, pre-adipocytes, adipocytes, vascular endothelial cells, endothelial progenitor cells, mesenchymal cells, smooth muscle progenitor cells, cardiac myocytes, epidermal keratinocytes, and capillary endothelial cells.

12 . The method of claim 3 , wherein the pharmaceutical composition further comprises a bioactive agent.

13 . The method of claim 12 , wherein the bioactive agent is selected from the group consisting of a hormone, an enzyme, an siRNA, an shRNA, an antisense-RNA, an antibiotic, an antibody, and an anti-inflammatory agent.

14 . The method of claim 3 , wherein the pharmaceutical composition is an aqueous solution.

15 . The method of claim 3 , wherein the pharmaceutical composition is a hydrogel.

16 . The method of claim 15 , wherein the hydrogel is characterized by having a storage modulus of at least 10 Pascal (Pa).

17 . The method of claim 3 , comprising providing the pharmaceutical composition in an article of manufacture, wherein the article is a syringe, a vial, an auto-injector, tubing, or a catheter.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2023
From: GIL, EUN SEOK; ALEKSI, ELTON; YAMAMOTO, NAOKI
To: 3-D MATRIX, LTD.
Reel/Frame 062663/0492 →
Continuity (3)
Continuation 16503039 · Jul 3, 2019
Provisional Application 62693877 · Jul 3, 2018
Related Publication 20230241157A1 · Aug 3, 2023
References Cited (23)
US 8951974B2 · Nagai · 2015 [cited by examiner]
US 11617778B2 · Gil et al. · 2023 [cited by applicant]
US 20180340188A1 · Gebeyehu · 2018 [cited by applicant]
US 20180360904A1 · Nagano et al. · 2018 [cited by applicant]
EP 2314325A2 · 2011 [cited by applicant]
WO 2011131671A1 · 2011 [cited by applicant]
WO 2017210416A1 · 2017 [cited by applicant]
WO 2020008377A2 · 2020 [cited by applicant]
Zhang Hangyu et al. “Rational design of charged peptides that self-assemble into robust nanofibers as immune-functional scaffolds”, Acta Biomaterialia, Elsevier, Amsterdam, NL. vol. 55, Mar. 30, 2017 (Mar. 30, 2017), pp… [cited by applicant]
Yuqiao Sun et al. “Self-assembly behaviors of molecular designer functional Rada 16-I peptides: influence of motifs, pH, and assembly time”, Biomedical Materials, Institute of Physics Publishing, Bristol, GB, vol. 12, N… [cited by applicant]
International Search Report and Written Opinion corresponding to PCT/IB2019/055661, Mailed Feb. 27, 2020, 9 pages. [cited by applicant]
International Preliminary Report on Patentability, PCT/IB2019/055661, mailed Jan. 1, 2021, 10 pages. [cited by applicant]
Batra et al. “Self-assembling peptide discovery: overcoming human bias with machine learning”, Nature Portfolio, 2021; DOI: https;//doi.org/10.21203/rs.3.rs-505801/v1 (2021). [cited by applicant]
Bork. Powers and Pitfalls in Sequence Analysis: The 70% Hurdle. Genome Research, 10:398-400 (2000). [cited by applicant]
Bowie et al. Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions. Science, 247:1306-1310 (1990). [cited by applicant]
Burgess et al. Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single L… [cited by applicant]
Greenspan et al. Defining epitopes: It's not as easy as it seems, Nature Biotechnology 17:936-937 (1999). [cited by applicant]
Lazar et al. Transforming Growth Factor alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, Mol. Cell. Biol., 8:1247-1252 (1988). [cited by applicant]
Zhang et al. Rational Design of Charged Peptides that Self-Assemble into Robust Nanofibers as Immune-Functional Scaffolds, Acta Biomater. Epub Mar. 30, 2017; 551:183-193 (2017). [cited by applicant]
3-D Matrix, Ltd., U.S. Appl. No. 16/503,039, allowed claims. [cited by applicant]
3-D Matrix, Ltd., U.S. Appl. No. 18/166,956, filed Feb. 9, 2023, pending claims. [cited by applicant]
Preliminary Amendment, filed Dec. 22, 2024, in US Reissue U.S. Appl. No. 18/991,623 to 3-D Matrix, Ltd. [cited by applicant]
Response to Nonfinal Office Action, filed Dec. 4, 2025, in U.S. Appl. No. 18/166,956 to 3-D Matrix, Ltd. [cited by applicant]